

Supplementary Data

Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer

Annika Eurola¹, Ari Ristimäki^{2,3}, Harri Mustonen¹, Anna-Maria Nurmi¹, Jaana Hagström^{2,4}, Caj Haglund^{*1} and Hanna Seppänen^{*1}

¹Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

²Department of Pathology, HUSLAB, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

³Applied Tumor Genomics (ATG), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland

⁴Department of Oral Pathology and Radiology, University of Turku, Turku, Finland

^{*}Shared equal last authorship

Supplementary Table 1.
Neoadjuvant treatments used.

	n (%)
Cisplatin–gemcitabine* (with or without radiation)	43 (48.9%)
Single gemcitabine (with or without radiation)	25 (28.4%)
FOLFIRINOX** (with or without radiation)	13 (14.8%)
Nab-paclitaxel–gemcitabine	5 (5.7%)
Capecitabine–gemcitabine	1 (1.1%)
Only radiation	1 (1.1%)
Radiation therapy used	26 (29.5%)
N (total)	88 (100%)

*One patient received Capecitabine after Cisplatin–Gemcitabine

**One patient received Cisplatin–Gemcitabine + radiation and one patient received Nab-paclitaxel–gemcitabine after FOLFIRINOX.

Supplementary Table 2.
Disease spesific survival multivariate analysis among non-responders.

	HR	95% CI	p value
Age	1,008	0,964–1,053	0,735
Stage III	1,639	0,751–3,579	0,215
Tumor size	1,005	0,979–1,033	0,693
Adjuvant therapy	0,559	0,271–1,151	0,114
Perivascular invasion	1,661	0,751–3,674	0,211
Podocalyxin			
weak	1		
moderate	1,293	0,528–3,167	0,574
strong	6,175	2,057–18,544	0,001

Abbreviations HR = Hazard ratio, CI = Confidence interval

Supplementary Table 3.

Disease free survival multivariate analysis among non-responders.

	HR	95% CI	p value
Age	1,008	0,963–1,055	0,737
Stage III	1,963	0,824–4,674	0,128
Tumor size	1,008	0,977–1,040	0,614
Adjuvant	0,600	0,300–1,197	0,147
Perivascular invasion	1,127	0,513–2,478	0,765
Podocalyxin			
weak	1		
moderate	0,933	0,397–2,193	0,874
strong	4,057	1,330–12,375	0,014

Abbreviations HR = Hazard ratio, CI = Confidence interval

Supplementary Table 4.

Progression free survival multivariate analysis among upfront surgery patients.

	HR	95% CI	p value
Age	1,001	0,980–1,024	0,897
Stage III	1,595	1,011–2,516	0,045
Tumor size	1,006	0,991–1,020	0,448
Adjuvant	0,568	0,382–0,846	0,005
Perivascular invasion	3,105	2,019–4,775	<0.001
Podocalyxin			
weak	1		
moderate	1,603	1,065–2,413	0,024
strong	7,135	3,297–15,444	<0.001

Abbreviations HR = Hazard ratio, CI = Confidence interval

Supplementary Table 5.

Disease specific multivariate analysis among upfront surgery patients.

	HR	95% CI	p value
Age	1,013	0,989–1,038	0,291
Stage III	1,482	0,975–2,253	0,066
Tumor size	1,013	0,998–1,027	0,085
Adjuvant	0,455	0,304–0,681	<0.001
Perivascular invasion	2,537	1,730–3,722	<0.001
Podocalyxin			
weak	1		
moderate	2,041	1,364–3,056	0,001
strong	4,165	2,601–6,669	<0.001

Abbreviations HR = Hazard ratio, CI = Confidence interval